RxDoctor Payments Data

Loida Campos Herrera

General Practice · Bayamon, PRNPI 1558361618

Payments from drug & device makers

$1,412in general payments, 2019–2025

Across 24 payments — averaging $58.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$312
  • Johnson & Johnson$226
  • Lilly USA, LLC$219
  • Boston Scientific$129
  • Novo Nordisk$125
  • Mylan Specialty L.p.$100
  • plus $301 from 6 others

What the payments were for

  • Food & beverage$1,412100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,412 in reported general payments places this provider in the 90th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$5,260
Medicare patients
18
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol11$17,829
SynthroidLevothyroxine Sodium118$14,064
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,672
Janumet XrSitagliptin Phos/Metformin Hcl11$11,395
Sucralfate14$4,036
Omega-3 Acid Ethyl Esters65$3,414
Candesartan Cilexetil13$2,129
Raloxifene Hcl20$1,927
Gabapentin116$1,889
Rosuvastatin Calcium106$1,766
LantusInsulin Glargine,hum.Rec.Anlog11$1,732
Metoprolol Succinate81$1,594
Losartan Potassium105$1,348
Pantoprazole Sodium83$1,312
Fluticasone Propionate65$1,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$68$17,82911 claims
AbbVieSynthroid$312$14,064118 claims
GSKTrelegy Ellipta$90$13,67213 claims
MerckJanumet Xr$57$11,39511 claims
Sanofi-aventis U.S. LLCLantus$18$1,73211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →